Amicus Therapeutics, Inc.
FOLD
$7.35
$0.152.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5.79% | 11.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.79% | 11.72% | |||
| Cost of Revenue | 11.73% | 17.92% | |||
| Gross Profit | 5.17% | 11.12% | |||
| SG&A Expenses | 15.39% | 2.08% | |||
| Depreciation & Amortization | -5.94% | -0.55% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.58% | 4.49% | |||
| Operating Income | -35.61% | 65.71% | |||
| Income Before Tax | 16.93% | 6,182.41% | |||
| Income Tax Expenses | -150.36% | -14.50% | |||
| Earnings from Continuing Operations | 319.04% | 57.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 319.04% | 57.13% | |||
| EBIT | -35.61% | 65.71% | |||
| EBITDA | -33.22% | 57.28% | |||
| EPS Basic | 317.65% | 57.25% | |||
| Normalized Basic EPS | -20.59% | 10,100.00% | |||
| EPS Diluted | 317.65% | 57.25% | |||
| Normalized Diluted EPS | -20.59% | 10,100.00% | |||
| Average Basic Shares Outstanding | 0.48% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||